OXLUMO (Medison Pharma Australia Pty Ltd)
Product name
OXLUMO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
154 (175 working days)
Active ingredients
lumasiran sodium
Registration type
NCE/NBE
Indication
Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) in all agegroups.